+

WO2010020789A3 - Médicament et traitement d'infections - Google Patents

Médicament et traitement d'infections Download PDF

Info

Publication number
WO2010020789A3
WO2010020789A3 PCT/GB2009/002043 GB2009002043W WO2010020789A3 WO 2010020789 A3 WO2010020789 A3 WO 2010020789A3 GB 2009002043 W GB2009002043 W GB 2009002043W WO 2010020789 A3 WO2010020789 A3 WO 2010020789A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
derivatives
alkaloids
antiviral agent
active substance
Prior art date
Application number
PCT/GB2009/002043
Other languages
English (en)
Other versions
WO2010020789A2 (fr
Inventor
Anant Sharma
Original Assignee
Anant Sharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anant Sharma filed Critical Anant Sharma
Publication of WO2010020789A2 publication Critical patent/WO2010020789A2/fr
Publication of WO2010020789A3 publication Critical patent/WO2010020789A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un médicament permettant de traiter des infections à transmission neurale, telles que l'herpès, le zona ou la rage. Ledit médicament comprend une première substance active sélectionnée parmi les alcaloïdes, les anesthésiques et la griséofulvine, et une seconde substance active comprenant un agent antiviral analogue de purine ou analogue de pyrimidine. Lesdits alcaloïdes peuvent comprendre la colchicine, la vinblastine, la vincristine, une cytochalasine ou leurs dérivés. Des analogues de purine adaptés incluent des dérivés de guanine N-substitués tels que l'aciclovir, le valaciclovir, le penciclovir, le famiciclovir ganciclovir, le valganciclovir ou des pro-médicaments qui se transforment ainsi dans le corps, et des dérivés d'adénine N-substitués tels que la vidarabine. Des analogues adaptés de pyrimidine incluent les dérivés de thymidine tels que la trifluorothymidine. Le médicament peut être administré par voie orale, par injection, par perfusion ou par voie topique ; un médicament topique peut inclure un anesthésique local. Ledit médicament peut être administré en réponse à un risque d'infection, avant le début de symptômes. On peut utiliser une combinaison de deux préparations, contenant respectivement la première et la seconde substance active, administrées séquentiellement ou simultanément.
PCT/GB2009/002043 2008-08-20 2009-08-20 Médicament et traitement d'infections WO2010020789A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0815179.7A GB0815179D0 (en) 2008-08-20 2008-08-20 Medication and treatment for infection
GB0815179.7 2008-08-20

Publications (2)

Publication Number Publication Date
WO2010020789A2 WO2010020789A2 (fr) 2010-02-25
WO2010020789A3 true WO2010020789A3 (fr) 2010-12-09

Family

ID=39812299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/002043 WO2010020789A2 (fr) 2008-08-20 2009-08-20 Médicament et traitement d'infections

Country Status (2)

Country Link
GB (1) GB0815179D0 (fr)
WO (1) WO2010020789A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159731A1 (fr) * 2013-03-13 2014-10-02 Nal Pharmaceuticals, Ltd Composition antivirale topique contenant un anesthésique local et son procédé de fabrication
CN108042589A (zh) * 2017-12-28 2018-05-18 漳州片仔癀药业股份有限公司 片仔癀及其制剂在制备治疗带状疱疹的药物中的新用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021565A1 (fr) * 1998-10-13 2000-04-20 Du Pont Pharmaceuticals Company Eradication selective des cellules infectees par des virus par l'utilisation combinee d'un agent cytotoxique et d'un agent antiviral
WO2006095178A1 (fr) * 2005-03-11 2006-09-14 Anant Sharma Medicament et traitement de l’herpes simplex

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021565A1 (fr) * 1998-10-13 2000-04-20 Du Pont Pharmaceuticals Company Eradication selective des cellules infectees par des virus par l'utilisation combinee d'un agent cytotoxique et d'un agent antiviral
WO2006095178A1 (fr) * 2005-03-11 2006-09-14 Anant Sharma Medicament et traitement de l’herpes simplex

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIJLENGA G ET AL: "Post-exposure Local Treatment of Mice Infected with Rabies with Two Axonal Flow Inhibitors, Colchicine and Vinblastine", JOURNAL OF GENERAL VIROLOGY 1978 GB, vol. 39, no. 2, 1978, pages 381 - 385, XP008122885, ISSN: 0022-1317 *
JOHNSON ROBERT W: "Herpes zoster: Predicting and minimizing the impact of post-herpetic neuralgia", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 47, no. Topic T1, February 2001 (2001-02-01), pages 1 - 8, XP000812287, ISSN: 0305-7453 *
SUGIMOTO Y ET AL: "COEXPRESSION OF A MULTIDRUG RESISTANCE GENE 7MDR1) AND HERPES SIMPLEX VIRUS THYMIDINE KINASE GENE IN A BICISTRONIC RETROVIRAL VECTOR HA-MDR-IRES-TK ALLOWS SELECTIVE KILLING OF MDR1-TRANSDUCED HUMAN TUMORS TRANSPLANTED IN NUDE MICE", CANCER GENE THERAPY, NORWALK, CT, US, vol. 4, no. 1, 1 January 1997 (1997-01-01), pages 51 - 58, XP000749200, ISSN: 0929-1903 *
YAMAMOTO N ET AL: "Anti-herpesvirus activity of citrusinine-I, a new acridone alkaloid, and related compounds", ANTIVIRAL RESEARCH, ELSEVIER BV, NL LNKD- DOI:10.1016/0166-3542(89)90065-X, vol. 12, no. 1, 1 August 1989 (1989-08-01), pages 21 - 36, XP024105616, ISSN: 0166-3542, [retrieved on 19890801] *

Also Published As

Publication number Publication date
GB0815179D0 (en) 2008-09-24
WO2010020789A2 (fr) 2010-02-25

Similar Documents

Publication Publication Date Title
Perry et al. Famciclovir: a review of its pharmacological properties and therapeutic efficacy in herpesvirus infections
Basha et al. A comprehensive review on pyrimidine analogs-versatile scaffold with medicinal and biological potential
US10010553B2 (en) Organic compounds
AU761694B2 (en) QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death
Neustadt et al. Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo [4, 3-e]-1, 2, 4-triazolo [1, 5-c] pyrimidines
De Clercq Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster
NL2000323C2 (nl) Pyrimidine-derivaten.
ES2340886T3 (es) Derivados de purina como agonistas del receptor a2a.
AR074879A1 (es) Formas salinas de un derivado de xantina, composiciones farmaceuticas que los contienen y su procedimiento de preparacion
WO2003063800A3 (fr) Antagonistes du recepteur a28 de l'adenosine a base de 8-heteroaryl xanthine
SG164390A1 (en) Hydrochlorides and hydrates of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7- (2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)xanthine, their preparation and their use as medicaments
WO2004024728A3 (fr) Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase
MY103760A (en) Therapeutic nucleosides
WO2014078778A3 (fr) Nucléosides antiviraux contenant de l'azasucre
JOP20210117A1 (ar) مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها
WO2008070313A3 (fr) Dérivés de 3-(dihydro-1h-pyrazolo [4,3-d]pyrimidin-5-yl)-4-propoxybenzènesulfonamide et procédés d'utilisation
AU627188B2 (en) Pharmaceutical products
WO2003022216A3 (fr) Derives de purine a substitution biaryle utilises comme agents antiproliferatifs puissants
WO2010020789A3 (fr) Médicament et traitement d'infections
Zangi et al. Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2
RU2008118995A (ru) Антагонист аденозинового рецептора а2а для изготовления лекарственного средства для лечения фибрилляции предсердий
WO2010085924A3 (fr) Dérivés de 6-(2-aminobenzylamino)purine substituée, utilisation de ceux-ci en tant que médicaments, et préparations contenant ces composés
US5446045A (en) Antiviral guanine analogs
EG et al. A review on therapeutic potential of heterocyclic pyrimidine derivatives as potent antiviral agents
Giorgi et al. 8-Azapurine nucleus: A versatile scaffold for different targets

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09784980

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09784980

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载